Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Appointed director

MyMD Pharmaceuticals, Inc. (AKER) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/04/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023"
08/24/2023 4 Rivard Paul (Chief Legal Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Bought 150,000 shares @ $1.11, valued at $166.5k
08/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application for Phase 2 Study of oral TNF-α inhibitor MYMD-1 ® in Rheumatoid Arthritis"
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Operator"
08/01/2023 8-K Quarterly results
07/31/2023 8-K Quarterly results
07/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/14/2023 8-K Other Events  Interactive Data
06/30/2023 ARS Form ARS - Annual Report to Security Holders:
06/30/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/09/2023 4 Chapman Christopher C JR (President, Chief Med. Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 300,000 options to buy @ $1.66, valued at $498k
06/09/2023 4 Kaplin Adam (Chief Scientific Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 150,000 options to buy @ $1.66, valued at $249k
06/09/2023 4 Uzonwanne Jude (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 150,000 options to buy @ $1.66, valued at $249k
06/09/2023 4 Schreiber Christopher C (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 150,000 options to buy @ $1.66, valued at $249k
06/09/2023 4 EAGLE CRAIG (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 475,000 options to buy @ $1.66, valued at $788.5k
06/09/2023 4 Silverman Joshua (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 200,000 options to buy @ $1.66, valued at $332k
06/09/2023 4 White Billy Joe (Director) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 150,000 options to buy @ $1.66, valued at $249k
06/09/2023 4 Rivard Paul (Chief Legal Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 150,000 options to buy @ $1.66, valued at $249k
06/09/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/05/2023 4 Chapman Christopher C JR (President, Chief Med. Officer) has filed a Form 4 on MyMD Pharmaceuticals, Inc.
Txns: Granted 750,000 options to buy @ $1.55, valued at $1.2M
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Third AMENDMENT TO EMPLOYMENT AGREEMENT"
03/22/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/22/2023 8-K Other Events  Interactive Data
03/20/2023 8-K Quarterly results
03/13/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/08/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls"
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Announces U.S. Drug Enforcement Administration Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical"
02/28/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "MyMD Pharmaceuticals Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy